AstraZeneca breast cancer drug gains marketing approval in EU

May 2004
PharmaWatch: Cancer;May 2004, Vol. 3 Issue 5, p7
Market Research Report
Reports that AstraZeneca PLC has received European marketing approval for its breast cancer drug Faslodex, which is indicated for the treatment of advanced breast cancer in post-menopausal women whose cancer has progressed on previous anti-oestrogen treatments. Company's plan to launch Faslodex in Europe in the second quarter of 2004; Clinical trial data on which the European marketing application for Faslodex was based.


Related Articles

  • Arimidex declared the new standard of care in breast cancer.  // PharmaWatch: Cancer;January 2005, Vol. 4 Issue 1, p17 

    Reports that medical journal "The Lancet" has published results from the world's largest and longest running early breast cancer trial showing that AstraZeneca PLC's Arimidex provides additional benefits over and above those offered by the previous standard of care, tamoxifen, in women with...

  • Breast cancer patients may be offered chemo-free treatment.  // PharmaWatch: Cancer;Jul2007, Vol. 6 Issue 7, p9 

    The article discusses the results of a study which reveal the efficacy of Zoladex, a hormonal drug designed by AstraZeneca PLC, in treating pre-menopausal breast cancer patients. According to the author, the drug is found to be as effective as traditional chemotherapy for the treatment of breast...

  • FDA approves new indication for Arimidex.  // Drug Topics;9/16/2002, Vol. 146 Issue 18, p10 

    Reports on the U.S. Food and Drug Administration's (FDA) approval of AstraZeneca's anastrozole (Arimidex) for the treatment of hormone receptor-positive early breast cancer in postmenopausal women. Improvement in recurrence-free survival; Findings from the Arimidex, Tamoxifen, Alone or in...

  • Not another magic bullet. Kent, Anne // BMJ: British Medical Journal (International Edition);09/09/2000, Vol. 321 Issue 7261, p644 

    Discusses the marketing campaign of Roche Pharmaceuticals for the launch of the breast cancer drug trastuzumab. Prohibitive cost of the drug; Physiological effect of the drug in patients with high levels of HER2 growth factor; Efforts of the company to highlight the drug's clinical benefits;...

  • JOINING FORCES.  // European Pharmaceutical Executive;Nov/Dec2006, p16 

    The article offers news briefs related to pharmaceutical companies. Schering AG and AstraZeneca made alliance to develop and commercialize the selective oestrogen receptor downregulator of Schering AG for breast cancer treatment. Pfizer Inc. and TransTech Pharma Inc. signed a license agreement...

  • AZ Finds Promising Sequel to Tamoxifen. Houlton, Sarah // Pharmaceutical Executive;Aug2002, Vol. 22 Issue 8, p18 

    Reports on the results of a clinical trial on AstraZeneca's Arimidex or anastrazole for treating breast cancer. Comparison with tamoxifen; Advantages of using the drug.

  • Symbicort and Seretide's battle for the respiratory market.  // PharmaWatch: Monthly Review;Aug2006, Vol. 5 Issue 8, p31 

    The article reports that AstraZeneca's new data showing a reduced mortality risk with Symbicort in chronic obstructive pulmonary disease patients, a reply to GlaxoSmithKline Corp.'s TORCH trial. Since the launches of Symbicort and Seretide in Europe, both firms have been trying to distinguish...

  • Drug combo helps women with early breast cancer.  // Tennessee Tribune;12/16/2010, Vol. 21 Issue 50, p11B 

    The article reports on the development of drug combination, Herceptin and Tykerb, that helps women with early breast cancer.

  • So, where's the cure?  // Redbook;Oct2011, Vol. 217 Issue 4, p116 

    The article reports that death rates from breast cancer is dropping with increase in treatments and medicines for specific types of cancer.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics